CareLit · DOI-Nachweis · Klinische Pädiatrie
Development of novel HDAC inhibitors to selectively co-inhibit HDAC8 and HDAC10 in childhood cancer
DOI 10.1055/s-0036-1582523
Bibliografische Angaben
Nachweis in CareLit
Autor:innenF Kolbinger, E Koeneke, J Senger, T Heimburg, T Bayer, M Jung, W Sippl, M Marek, C Romier, N Gunkel, AK Miller, P Sehr, O Witt, I Oehme
ZeitschriftKlinische Pädiatrie
Ausgabe05/2016
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Introduction: Histone deacetylases (HDACs) are validated targets in antitumoral therapy, and five pan-HDAC inhibitors have been clinically approved to date. Dosage of these inhibitors is limited due to side effects (e.g. leukopenia, diarrhea, fatigue) mainly attributed to HDAC1, 2 and 3 inhibition. High HDAC8 and high HDAC10 co-expression correlate with exceptionally poor outcomes in neuroblastoma. Preliminary studi…
Zitieren
Zitierempfehlung
F Kolbinger, E Koeneke, J Senger, T Heimburg, T Bayer, M Jung, W Sippl, M Marek, C Romier, N Gunkel, AK Miller, P Sehr, O Witt, I Oehme (2016) Development of novel HDAC inhibitors to selectively co-inhibit HDAC8 and HDAC10 in childhood cancer. Klinische Pädiatrie (05). https://doi.org/10.1055/s-0036-1582523
Mit CareLit weiterarbeiten